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Background: Systemic anaplastic large cell lymphoma (S-ALCL) is a rare disease with a highly variable prognosis
and no standard chemotherapy regimen. Anaplastic lymphoma kinase (ALK) has been reported as an important
prognostic factor correlated with S-ALCL in many but not all studies. In our study, we retrospectively analyzed 92
patients with S-ALCL from the Peking University Lymphoma Center for clinical and molecular prognostic factors to
make clear the role of ALK and other prognostic factors in Han Chinese S-ALCL.
Results: The majority of Chinese S-ALCL patients were young male patients (median age 26, male/female ratio 1.7) and
the median age was younger than previous reports regardless of ALK expression status. The only statistically significant
different clinical characteristic in S-ALCL between ALK positive (ALK+) and ALK negative (ALK-) was age, with a younger
median age of 22 for ALK+ compared with 30 for ALK-. However, when pediatric patients (≤18) were excluded, there
was no age difference between ALK+ and ALK-. The groups did not differ in the proportion of males, those with clinical
stage III/IV (49 vs 51%) or those with extranodal disease (53 vs 59%). Of 73 evaluable patients, the 3-year and 5-year
survival rates were 60% and 47%, respectively. Univariate analysis showed that three factors: advanced stage III/IV, lack
of expression of ALK, and high Ki-67 expression, were associated with treatment failure in patients with S-ALCL.
However, ALK expression correlated with improved survival only in patients younger than 14 years, while not in adult
patients. In multivariate analysis, only clinical stage was an independent prognostic factor for survival. Expressions of
Wilms tumor 1 (WT1) and B-cell lymphoma 2 protein (BCL-2) correlated with the expression of ALK, but they did not
have prognostic significance. High Ki-67 expression was also a poor prognostic factor.
Conclusions: Our results show that ALK expression alone is not sufficient to determine the outcome of ALCL and
other prognostic factors must be considered. Clinical stage is an independent prognostic factor. Ki-67 expression is a
promising prognostic factor.
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Primary anaplastic large cell lymphoma (ALCL) occurs as a
systemic form (S-ALCL) and a cutaneous form, which are
clinically and pathologically distinct disorders of mature T
cells. S-ALCL, first described by Stein and colleagues in
1985 [1], accounts for only 2–8% of non-Hodgkin’s* Correspondence: xiaoyank@yahoo.com
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reproduction in any medium, provided the orlymphomas in adults and 10–15% in children [2]. About
60% of S-ALCL express anaplastic lymphoma kinase
(ALK), a chimeric protein with tyrosine kinase activity that
is most commonly created by a unique chromosomal trans-
location t(2;5)(p23;q35) resulting in the fusion of the ALK
gene with the nucleophosmin (NPM) gene [3,4].
S-ALCL is highly variable in morphology, phenotype,
and clinical course. The prognosis of S-ALCL has been
reported to correlate with the expression of ALK [5,6].
ALK+ S-ALCL often occurs in males younger than 30 years
and is associated with a more favorable prognosis, whiletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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affects both genders and has an unfavorable prognosis.
However, different reports have reached various conclu-
sions about the correlation of various prognostic factors
with survival [6-10], and these reports also have conflict-
ing data regarding features associated with ALK+ versus
ALK- S-ALCL. For example, Gascoyne et al. [6] found that
ALK expression, age, performance status, lactate dehydro-
genase (LDH), extranodal disease, and international prog-
nostic index (IPI) were significant prognostic factors,
while stage was not a predictor of outcome. Falini et al.
[7] also showed that ALK+ and a low or low-intermediate
IPI were independent variables predicting survival in
multivariate analysis. One of the largest studies [8], a
multinational collaboration involving 22 institutions and
159 patients with S-ALCL, reported that stage, LDH, and
IPI were prognostic factors, but ALK expression was a fa-
vorable prognostic factor only in younger patients. Park
et al. [9] reported that IPI and age were predictors of out-
come, whereas ALK expression did not affect prognosis.
Another retrospective study from Sibon et al. [10]
reported that ALK expression affected prognosis only for
older patients and ALK was not an independent prognos-
tic factor.
Our previous study showed that the prevalence and
clinical and laboratory characteristics of lymphomas
among Han people in China may be different from that
in other populations [11,12], suggesting that genetic
background and environmental factors may affect the
genesis, expression of biomarkers, and prognosis of
lymphomas. So, it is necessary to analyze the clinical fea-
tures associated with ALK+ and ALK- in a Han Chinese
patient population and their prognostic significance. Fur-
thermore, in order to find a better combination of prog-
nostic factors for S-ALCL, we also focused on
identifying other prognostic biomarkers for S-ALCL. A
number of biomarkers have been identified as prognostic
factors in various hematopoietic malignancies [13-22].
Since stress-induced apoptosis is a primary pathway
involved in chemotherapy-induced cell death [23,24], we
set up to determine whether some apoptosis-related bio-
markers have potential prognostic value in S-ALCL. B-
cell lymphoma 2 (BCL-2), an anti-apoptotic gene, is
expressed in several subtypes of lymphomas, wherein a
high level of expression of BCL-2 has been associated
with poor outcome [13-15]. The expression of Ki-67, a
nuclear antigen protein, is used as a reflection of prolif-
eration and metastatic potential of non-Hodgkin's
lymphoma (NHL) [16,17]. Wilms tumor 1 (WT1) is a
tumor suppressor gene and a regulator of apoptosis [18],
which is expressed in various types of solid tumors and
several hematologic malignancies. WT1 expression is
considered an unfavorable prognostic marker in acute
leukemia [19-21] and WT1 expression is also detectedin S-ALCL [22]; however, the prognostic value of BCL-2,
WT1, and Ki-67 in S-ALCL remains to be determined.
In this study, we retrospectively analyzed the data of
92 patients with S-ALCL from a single referral center,
the Peking University Lymphoma Center, for clinical fea-
tures, expression rates of ALK, BCL-2, WT1 and Ki-67,
and their association with outcome to determine poten-




During a ten-year period from 2001 to 2011, 92 S-ALCL
patients at the Peking University Third Hospital and the
Lymphoma Laboratory of Peking University Health Sci-
ence Center were enrolled in the study. Primary cutane-
ous anaplastic large-cell lymphoma was excluded from
the study. Of the 92 cases, 38 cases were pediatric
patients with age of 18 years or younger. In accordance
with a protocol approved by the medical ethics commit-
tee at Peking University Health Science Center, retro-
spective analyses on the patients’ data were carried out.
Data collected included: age, gender, Ann Arbor clinical
stage, date of diagnosis, disease sites (nodal or extrano-
dal), presence of B symptoms, and survival status. Ann
Arbor stage [25] was determined by utilizing history,
physical examination, chest, abdominal and pelvic com-
puted tomography scans, and bone marrow aspirate and
biopsy. If abnormal lymphocytes were found by any of
the methods used, including cytomorphologic inspection
of bone marrow smear, biopsy or flow cytometry, we
thought that the patient have bone marrow involvement.
There were not primary or acquired immunodeficiency
diseases in our cases. All patients received CHOP or
CHOP-like combination chemotherapy regimens. Treat-
ment outcome was determined by overall survival (OS),
which was defined as the time from diagnosis to the last
contact date or to death from any cause, with 19 patients
lost to follow up and unavailable for survival analyses.
Histopathologic analysis
The S-ALCL patients were diagnosed according to the
World Health Organization Classification [26]. The diag-
nosis of S-ALCL was based both on the histopathologic
presence of large cells with anaplastic morphology (pleo-
morphic nuclei, prominent nucleoli, and abundant cyto-
plasm) and on the expression of CD30 antigen by the
tumor cells. There is no clear difference in the morpho-
logical features between ALK+ and ALK- ALCL and the
criteria that divide S-ALCL into ALK+ and ALK- sub-
groups is based on the expression of ALK. CD30 is also
an important index to distinguish ALK- ALCL from per-
ipheral T cell lymphoma, NOS; CD15, CD45, and PAX-5
were used to exclude Hodgkin lymphoma from the
Table 1 Clinical characteristic of S-ALCL patients,
according to ALK expression
Clinical feature ALK+ S-ALCL ALK- S-ALCL P
patients no. 51 41
Median age (all patients)
(range), y
22(3–63) 30(2–74) <0.05
Median age (without pediatric
patients) (range), y
38(19–63) 34(19–74)






location of tumor, no. (%) 0.675
nodal 24(47) 17(41)
extranodal 27(53) 24(59)
B symptom, no. (%) 0.095
with 28(55) 15(37)
without 23(45) 26(63)
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EBER. HTLV-1 is not a routine test for S-ALCL in our
pathological laboratory.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissue samples from
the 92 patients were used for further immunohistochem-
ical analyses. BCL-2, WT1, Ki-67, and ALK in tissue sec-
tions were immuno-stained using specific antibodies
followed with the diaminobenzidine (DAB) histochemis-
try kit (Molecular Probes, Invitrogen, California, USA)
as we previously reported [12]. Briefly, 4 μm thick tissue
sections from paraffin blocks were de-paraffinated and
heat-retrieved for antigens in target retrieval solution
(pH 6.0) in a microwave oven for 2–3 min, depending
on the size of the section. Sections were then incubated
with anti-BCL-2, WT1, Ki-67, and ALK antibodies
(Dako-China Branch, Shanghai, China), respectively, for
one hour followed by biotinylated rabbit anti-mouse
antibody and horseradish peroxidase (HRP)-conjugated
avidin. Finally, DAB staining on the sections were visua-
lized under bright field light microscopy. The expres-
sions of WT1 and BCL2 in tissues were divided into
positive and negative groups using 10% as a threshold
value [27]. The proliferation index was calculated as the
ratio of Ki-67 positive nuclei with respect to the total
number of neoplastic cells, which was used to classify
tumors into two types, low proliferation (≤30% Ki-67
positive neoplastic cells) or high proliferation (>30% Ki-
67 positive neoplastic cells) [28] .
Statistical analysis
Estimates of OS and univariate analyses of prognostic
factor were performed by using the Kaplan-Meier
method. The positive rates of biomarkers in S-ALCL
were analyzed by using the Chi-square test. Multivariate
analyses were performed with the Cox proportional haz-
ard regression model (enter and remove limits 0.1). P
values below 0.05 were considered to be significant. All
the analyses were performed using the SPSS statistical
software package (version 13.0, SPSS, Chicago, USA).
Results
Gender, age, and stage composition of Chinese S-ALCL
patients
Of the 92 patients with S-ALCL, 58 were male and 34
were female, for a male/female ratio of 1.7. The median
age was 26 years (range 2 to 74) and 38 patients (41%)
were 18 years or younger. Clinical staging analysis
showed that 50% patients were stage III to IV and 47%
patients had systemic B symptoms, predominantly fever.
Forty-one patients (45%) had nodal-only disease, but the
majority (55%) had extranodal tissue involvement, in-
cluding lung, bone marrow, liver, spleen, and skin.Histopathology and immunophenotype
Most of the cases had the typical pleomorphic cytology
and sinusoidal infiltration. So-called hallmark cells with
eccentric horse-shoe or kidney-shaped nuclei were
present both in ALK+ or ALK- cases. Five cases (5%) of
small-cell variant of ALCL were included in the study.
61 cases (66%) were common “T cell” phenotype with
the expression of CD3 and/or CD43, and CD45RO. 31
cases (34%) had an apparent “null cell” phenotype. EBV
was consistently negative in all S-ALCL cases.
Clinical features stratified by expression of ALK
The clinical features stratified by expression of ALK are
shown in Table 1. Patients with ALK+ S-ALCL were sig-
nificantly younger than those with ALK- S-ALCL (me-
dian age 22 vs. 30 years) (P<0.05), but both subgroups
had a predominance of males, and a similar proportion
of stage III/IV disease (ALK+ 49%; ALK- 51%). B symp-
toms were present in 55% of ALK+ and in 37% of ALK-
patients, but this did not reach statistical significance.
Extranodal involvement was similarity in ALK+ vs. ALK-
(53 vs. 59%). Although not statistically significant, the
most common sites of involvement in ALK+ S-ALCL
were subcutaneous tissue (14%), lung (14%), skin (10%),
and bone (6%), and in ALK- S-ALCL were skin (20%),
spleen (15%), lung (10%) and bone (10%). The frequency
of bone marrow involvement was lower in ALK+ S-
ALCL (0% vs. 5% in ALK- ALCL), but this was also not
statistically significant (Table 2).
Furthermore,54 patients aged 19 years or older were
analyzed separately, with the following findings (Table 3).
Table 2 Extranodal sites of involvement in ALK+ and ALK-
S-ALCL
Extranodal sites ALK+ S-ALCL(%) ALK- S-ALCL(%) P
Bone marrrow 0 2(5) 0.196
Subcutaneous tissue 7(14) 3(7) 0.503
Lung 7(14) 4(10) 0.749
Bone 3(6) 4(10) 0.696
Skin 5(10) 8(20) 0.234
Liver 2(4) 3(7) 0.653
Spleen 2(4) 6(15) 0.133
Epidural 0 1(2) 0.446
Pleural effusion 2(4) 2(5) 1
Pericardial effusion 0 2(5) 0.196
Table 3 Clinical features of Chinese S-ALCL compared
with Savage’s report











23 87 31 72
Median age, y 38 34 34 58
Age less than
60 y, no. (%)
22(96) 74(86) 0.175 26(84) 42(58) <0.05
Male–female ratio 2.8:1 1.7:1 0.34 1.8:1 1.5:1 0.68
Stage, no.(%) 0.07 0.53
I 9(40) 1(0) 8(26) 0(0)
II 4(17) 30(35) 7(23) 30(42)
III 6(26) 25(29) 10(32) 15(21)
IV 4(17) 31(36) 6(20) 27(37)
Nodal-only disease,
no. (%)




4(17) 17(19.5) 0.82 5(16) 15(21) 0.58
Extranodal sites,
no. (%)
Bone marrrow 0 10(12) 0.09 2(5) 5(7) 0.93
Subcutaneous
tissue
0(0) 9(10) 0.1 1(3) 2(3) 0.9
Lung 2(8) 7(8) 0.92 1(3) 9(13) 0.14
Bone 3(6) 12(14) 0.93 2(5) 5(7) 0.93
Skin 5(10) 7(8) 0.06 5(16) 12(17) 0.95
Liver 1(4) 3(3) 0.84 2(6) 7(10) 0.59
Spleen 1(4) 9(10) 0.37 4(13) 2(3) <0.05
Pleural effusion 1(4) 3(3) 0.84 2(6) 4(6) 0.86
Pericardial
effusiom
0(0) 0(0) 0.6 1(3) 1(1) 0.54
B symptoms, no. (%) 9(39) 52(60) 0.08 11(35) 41(57) <0.05
5-y OS, % 58 70 35 49
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group and 34 years in the ALK- S-ALCL group. B symp-
toms were present in 39% of ALK+ and in 35% of ALK-
patients. Forty-three percent of ALK+ patients had stage
III/IV disease versus 52% of ALK-. The most common
extranodal sites in this patient population were skin
(10%), lung (8%), and bone (6%) for ALK+ patients, and
skin (16%), spleen (13%), liver (6%), and pleural effusion
(6%) for ALK- patients.
Achievement of CR is associated with a longer median
survival time
Of the 73 evaluable patients, the median time of follow-up
was 67 months (range 0.5 months to 128 months). We
determined the overall survival (OS) of patients using the
Kaplan-Meier analytic method. The mean survival time of
the 73 evaluable patients was 67 months (95% confidence
intervals: 53–80 months) and the 3- and 5-year OS rates
were 60% and 47%, respectively (Figure 1). Among the 34
surviving patients, 26 (76%) patients had achieved a
complete remission (CR) after induction chemotherapy, 7
(21%) had a partial remission (PR), and 1 (3%) patients
was primary refractory. The median survival time of the
patients with a CR was significantly longer than others
(77 months vs.59 months, P<0.05). Of the 39 deceased
patients, 22 (56%) died in the first year after diagnosis and
28 (72%) had stage III–IV disease.
Stage is an independent prognostic factor for survival
The following clinical variables were evaluated for the 73
evaluable patients to determine their utility in predicting
prognosis: age, gender, stage, extranodal involvement,
and B symptoms. However, only the clinical stage signifi-
cantly correlated with prognosis in univariate analysis.
The 5-year OS rates for patients with stage I, II, III, IV
were 78%, 59%, 28%, and 14%, respectively (P<0.05)
(Figure 2A). Furthermore, the prognostic value of stage
could be seen in ALK- S-ALCL, while not in ALK+ S-
ALCL. In the 33 ALK- cases, the 5-year OS rate for stage
I/II was 58% and for stage III/IV was 20% (P<0.05)
(Figure 2B), which suggest that ALK- S-ALCL patients
could be further divided into different risk groups
according to clinical staging. In addition, stage correlated
with prognosis both for pediatric patients (P<0.05) and
adult patients (P<0.05), suggesting that stage is not
affected by age. Furthermore, we found that the clinical
stage remained a significant prognostic factor in multi-
variate analysis (P<0.05).
ALK expression is associated with a better OS, but only in
patients 14 years old or younger
Fifty-five percent of the 92 cases were ALK positive. As
shown in Figure 3, the rate of ALK expression was sig-
nificantly higher in pediatric patients compared with
Figure 1 Overall survival (OS) of the 73 evaluable patients with
S-ALCL. The median survival time is 67 months and the 5-year OS
rate is 47%. n = total number of the evaluable patients with S-ALCL.
Figure 3 Distribution of ALK+ and ALK- S-ALCL patients by age
groups. n= total patient numbers in each group.
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with 42% of those >18 years (P<0.05)). Using Kaplan-
Meier analysis, we examined the influence of ALK on
the OS and found that patients with ALK+ S-ALCL had
a more favorable prognosis than patients with ALK- S-
ALCL (P<0.05). The 5-year OS rates in the ALK+ group
and the ALK- group were 58% and 36%, respectively
(Figure 4). Surprisingly, the prognostic value of ALK in
pediatric and adult patients was different. The favorable
prognosis of ALK+ S-ALCL was seen in the population
≤14 years old (P= 0.05), but not in those older than
14 years. However, in multivariate analysis, when other
clinical factors and biomarkers were added, ALK was no
longer a prognostic factor, regardless of age.Figure 2 Overall survival by Ann Arbor stage. (A) The 5-year OS of 73 e
and 14%, respectively (P = 0.000). (B) The 5-year OS of 33 patients with ALK
n= patient numbers in each group.High expression of Ki-67 is associated with a poorer
prognosis
The expression of Ki-67 was analyzed in 74 of 92 S-
ALCL cases and the results for the ALK+ and ALK-
groups are shown in Table 4. The median expression of
Ki-67 in lymphoma cells was 71% (5–95%) and Ki-67’s
expression was not statistically correlated with the ex-
pression of ALK, with a median expression of Ki-67 in
the ALK+ and ALK- group of 60% and 80%, respectively.
Seventy-four percent of S-ALCL had high-expression
(>30%) of Ki-67 and 26% had low-expression (≤30%)
(Table 4), suggesting that most S-ALCL has a high pro-
liferating status.
On further evaluation of 56 patients, we found that
patients with Ki-67 low-expression had a better outcome
compared with those with Ki-67 high-expression, with a
5-year OS of 100% versus 39% (P<0.05), (Figure 5).
When the analysis was limited to the ALK+ or ALK- S-
ALCL patients, Ki-67 high-expression was not avaluable patients with S-ALCL by stage I, II, III and IV is 78%, 59%, 28%
- S-ALCL by stage I/II and III/IV is 58% and 20%, respectively (P = 0.016).
Figure 4 Overall survival of the 73 evaluable patients with S-
ALCL by expression of ALK. The 5-year OS of ALK+ S-ALCL and
ALK- S-ALCL is 58% and 36%, respectively (P = 0.044). n = patient
numbers in each group.
Figure 5 Overall survival stratified by Ki-67 expression. The 5-
year OS of ki-67 low expression S-ALCL and ki-67 high expression S-
ALCL is 100% and 39%, respectively (P = 0.013). n = patient numbers
in each group.
Wang et al. Journal of Hematology & Oncology 2012, 5:38 Page 6 of 9
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of Ki-67 in pediatric patients (P<0.05), but not in adult
patients, suggesting that the role of Ki-67 could be
affected by age. Further, in multivariate analysis, Ki-67
high-expression is no longer correlated with poorer
prognosis.
BCL-2 expression is inversely correlated with ALK
expression but is not significantly associated with
prognosis
BCL-2 expression in tumor cells was examined in 59
cases. Overall, 11 (19%) patients were BCL-2 positive.Table 4 Relation of expression between Ki-67, BCL-2, WT1
and ALK
Index ALK total χ2 P
(+) (−) no.(%)
Ki-67 0.268 >0.05
low-expression, no. 12 7 19(26)
high-expression, no. 31 24 55(74)
total, no. 43 32 74(100)
BCL-2 5.336 <0.05
(+), no. 4 7 11(19)
(−), no. 35 13 48(81)
total, no. 39 20 59(100)
WT1 4.479 <0.05
(+), no. 27 8 35(61)
(−), no. 11 11 22(39)
total, no. 38 19 57(100)No differences were observed between the BCL-2-
positive group and BCL-2-negative group in gender, age,
nodal involvement, and clinical stage. The expression of
BCL-2 was significantly inversely associated with the ex-
pression of ALK, with BCL-2 positivity in 10% (4 of 39)
of the ALK+ group and 35% (7 of 20) of the ALK- group
(P<0.05) (Table 4).
Although previous studies reported that BCL-2 ex-
pression is related to poor clinical outcome in several
lymphomas [13,14], we did not find any prognostic value
of BCL-2 expression in patients with S-ALCL in neither
univariate analysis nor in multivariate analysis.
WT1 expression is positively correlated with ALK
expression but is not significantly associated with
prognosis
To address if WT1 expression is a prognostic factor in
S-ALCL, we performed immuno- histochemical staining
of WT1 in 57 cases and found positive expression of
WT1 in 35 (61%) cases. Table 4 summarizes the expres-
sion of WT1 in the ALK+ group and the ALK- group.
WT1 expression positively correlated with ALK expres-
sion. WT1 positive rates were 71% (27 of 38)and 42% (8
of 19)in the ALK+ group and the ALK- group, respect-
ively (P< 0.05). However, WT1 over-expression was not
a prognostic factor for patients with S-ALCL neither in
univariate analysis nor in multivariate analysis.
Discussion
S-ALCL is a lymphoma with an aggressive and heteroge-
neous clinical course, primarily occurring in children
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response of ALCL to chemotherapy was good, especially
in children, ranging from 60%–90% [2,9,29]. However,
for patients at high-risk for treatment failure, other ther-
apies such as high-dose chemotherapy followed by stem
cell therapy may be needed to improve the long-term
survival [30]. Therefore, identification of prognostic fac-
tors would aid clinicians in selecting an optimal thera-
peutic regimen.
In this study, we analyzed clinical characteristics and
prognostic factors in Han Chinese patients with S-ALCL
from a single referral center. We found some unique
clinical features in our S-ALCL patients. The median
age of our patients was 26 years regardless of ALK ex-
pression status, and even when pediatric patients were
excluded, the median age of ALK- S-ALCL was 34,
which is much younger than other reports [6-10,30-32].
The percentage of patients with clinical stages III/IV in
our study was also less than previous reports (50 vs.
56%–72%) [6-10,30-32]. Since some studies [8,33]
excluded pediatric patients, we also analyzed the subset
of patients aged 19 years or older and compared the
results to those reported by Savage et al.[8]. We found
that some of the clinical features of ALK+ S-ALCL in
our analysis were similar to those in Savage et al., but
Chinese patients with ALK- S-ALCL are younger (me-
dian age 34 vs. 58), with a lower percentage of B symp-
toms (35 vs. 57%), and different sites and frequency of
extranodal involvement, compared to those reported by
Savage et al. [8]. Our study found that skin, spleen, lung,
and bone were common sites in ALK- S-ALCL, while in
Savage’s report bone marrow, subcutaneous tissue, bone,
liver, and spleen were often involved. The 5 year-OS of
our S-ALCL patients was also lower than Savage’s re-
port; however, their patient population had varied ethnic
backgrounds (25% North American, 24% European, and
40% Asian), which might account for some of these
differences.
Our study found that patients who had a CR following
induction chemotherapy had a more favorable prognosis,
suggesting that achieving a CR during induction chemo-
therapy is a principal factor of longer OS. In our cohort
of patients, most deaths occurred in the first year after
diagnosis, which indicates that S-ALCL is a rapidly fatal
disease and effective induction chemotherapy is essential
for long-term survival.
Although previous studies [6,7] identified several clin-
ical characteristics, such as advanced clinical stage, older
age, extranodal involvement, and B symptoms with a
high-risk disease, clinical stage was the only independent
clinical prognostic marker in our study. None of the
other clinical factors had statistical significance whether
by univariate analysis or by multivariate analysis, consist-
ent with the report by Savage et al. [8]. In addition tothe clinical characteristics, we also analyzed the expres-
sion of several tumor biomarkers. We found for the first
time that Ki-67 had prognostic significance in S-ALCL.
Furthermore, the expression of Ki-67 also defined differ-
ent risk categories in patients with ALK- S-ALCL, al-
though not in ALK+ S-ALCL.
ALK+ S-ALCL may have a more favorable clinical
course than ALK- S-ALCL [6-8], but recent study found
that activation of ALK could provides oncogenic addiction
to tumors harboring activating mutation or translocation
of ALK such as in non-small cell lung cancer, so ALK in-
hibitor may be a potent novel targeted therapeutic in some
solid tumor [34]. In our Han Chinese patients, the 5-year
OS was 58% in ALK+ S-ALCL patients versus 36% in
ALK- S-ALCL patients, which was lower than other
reports showing 70%-80% survival in ALK+ versus 33%-
49% in ALK- S-ALCL [6,7,31,32]. Though poorer outcome
for ALK- S-ALCL patients, they may be divided into differ-
ent groups by stage or expression of Ki-67. Recently, Sav-
age et al. [8] found that the favorable outcome of ALK+ S-
ALCL was restricted to younger patients and no outcome
differences were seen between the ALK+ and ALK- groups
in patients over 40 years old. In contrast, Sibon et al. [10]
reported that there was no impact of ALK status on sur-
vival in patients younger than 40 years old and Park et al.
[9] also reported no predictive value for ALK expression.
Wang et al. [35] thought that suppressor Tregs in ALK+
S-ALCL could suppress the anti-tumor immune response
induced by effector T cells, which maybe weaken the role
of ALK. Besides, Beltran et al. [36] found the favorable
prognostic role of ALK expression in DLBCL and the clin-
ical course of ALK- DLBCL was aggressive. Compared to
the previous reports, in our study, the favorable prognostic
influence of ALK expression seems to be confined to
pediatric patients. In univariate analysis, in patients who
are 14 years old or younger, the ALK+ group had better
survival rate than ALK- group, but this survival difference
was not present in patients older than 14 years. Neverthe-
less, in multivariate analysis, ALK was no longer a signifi-
cant prognostic factor whether in pediatric or adult
patients. These results suggest that the prognostic value of
ALK expression may be affected by other as yet unknown
factors. Clinical stage or biomarkers may ultimately be
more important predictors of prognosis.
It is not known why some patients with ALK+ S-ALCL
have better outcomes. One study showed that the tumor
cells of ALK+ S-ALCL could be associated with higher
levels of apoptosis by chemotherapeutic drugs than those
of ALK- S-ALCL [37]. Stress-induced apoptosis is a path-
way involved in chemotherapy-induced cell death, and
BCL-2 may inhibit the cell death pathway by suppressing
the function of pro-apoptotic molecules [23,24]. Previous
studies found that BCL-2 expression is almost completely
restricted to ALK- S-ALCL and is correlated with a poor
Wang et al. Journal of Hematology & Oncology 2012, 5:38 Page 8 of 9
http://www.jhoonline.org/content/5/1/38outcome [13,14], however, in our study, BCL-2 expression
did not have a significant influence on long-term survival,
although the expression of BCL-2 was more frequently
found in ALK- patients than in ALK+ S-ALCL patients.
Nevertheless, to fully evaluate the role of BCL-2 in S-
ALCL, a larger number of samples would be needed.
The role of WT1 as an unfavorable prognostic marker
has been confirmed in acute leukemia and some of solid
tumors [20,21]. Unlike its role in acute leukemia, WT1
was not a significant prognostic factor in S-ALCL in our
study. Over-expression of WT1 was more frequently
found in ALK+ S-ALCL and there was a significant posi-
tive correlation between the expression of WT1 and
ALK. This may indicate that ALK expression is affected
by multiple factors and may explain why ALK was no
longer a prognostic marker in our multivariate analysis.
The functional interaction of ALK and WT1 in S-ALCL
is a worthwhile target for future studies, although larger
studies are required to validate the prognostic value of
WT1 expression in S-ALCL.
In conclusion, the Han Chinese patients with S-ALCL
in our study had some unique clinical features, including
younger age distribution and a slightly higher percentage
of early stage. Our data add to other reports stressing a
potential contribution of ethnic and racial background
on clinical and biological characteristics of hematological
malignancies. Similar to other reports, in our study the
expression of ALK and Ki-67 and clinical stage are sig-
nificant prognostic factors for S-ALCL patients in uni-
variate analysis. However, clinical stage is the only
independent prognostic marker in multivariate analysis.
Nevertheless, it is possible that these prognostic factors
may play a role in different age groups and different
populations. A larger scale and preferably multi-
institutional study will be needed to confirm the prog-
nostic role of geographical or ethnic differences. Further
characterization of these and other prognostic factors in
S-ALCL patients will provide better prognostic guidance
for stratifying patients for future therapeutic trials.
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